

Georgios Vlachogiannis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8672172/publications.pdf>

Version: 2024-02-01

11
papers

1,823
citations

933447

10
h-index

1281871

11
g-index

12
all docs

12
docs citations

12
times ranked

4082
citing authors

#	ARTICLE	IF	CITATIONS
1	Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. <i>Science</i> , 2018, 359, 920-926.	12.6	1,199
2	Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical Trial. <i>Cancer Discovery</i> , 2018, 8, 1270-1285.	9.4	187
3	Serine synthesis pathway inhibition cooperates with dietary serine and glycine limitation for cancer therapy. <i>Nature Communications</i> , 2021, 12, 366.	12.8	138
4	Exploiting evolutionary steering to induce collateral drug sensitivity in cancer. <i>Nature Communications</i> , 2020, 11, 1923.	12.8	79
5	A MYC-eIF2 γ negative feedback loop limits protein synthesis to prevent MYC-dependent apoptosis in colorectal cancer. <i>Nature Cell Biology</i> , 2019, 21, 1413-1424.	10.3	65
6	MNK Inhibition Sensitizes KRAS-Mutant Colorectal Cancer to mTORC1 Inhibition by Reducing eIF4E Phosphorylation and c-MYC Expression. <i>Cancer Discovery</i> , 2021, 11, 1228-1247.	9.4	45
7	miR-31-3p Expression and Benefit from Anti-EGFR Inhibitors in Metastatic Colorectal Cancer Patients Enrolled in the Prospective Phase II PROSPECT-C Trial. <i>Clinical Cancer Research</i> , 2019, 25, 3830-3838.	7.0	42
8	Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer. <i>Oncogene</i> , 2019, 38, 1717-1733.	5.9	29
9	EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancers. <i>Gut</i> , 2021, 70, 1632-1641.	12.1	24
10	MIR21-induced loss of junctional adhesion molecule A promotes activation of oncogenic pathways, progression and metastasis in colorectal cancer. <i>Cell Death and Differentiation</i> , 2021, 28, 2970-2982.	11.2	13
11	A phospho-proteomic study of cetuximab resistance in KRAS/NRAS/BRAFV600 wild-type colorectal cancer. <i>Cellular Oncology (Dordrecht)</i> , 2021, 44, 1197-1206.	4.4	2